{"id":391501,"date":"2014-11-14T00:00:00","date_gmt":"2014-11-14T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/pforeu0414-biopharma-hepatitis-c-virus-how-will-all-oral-interferon-free-antiviral-regimens-influence-physician-and\/"},"modified":"2026-04-17T23:44:33","modified_gmt":"2026-04-17T23:44:33","slug":"pforeu0414-biopharma-hepatitis-c-virus-how-will-all-oral-interferon-free-antiviral-regimens-influence-physician-and","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/pforeu0414-biopharma-hepatitis-c-virus-how-will-all-oral-interferon-free-antiviral-regimens-influence-physician-and\/","title":{"rendered":"Hepatitis C Virus (How Will All-Oral, Interferon-Free Antiviral Regimens Influence Physician and Payer Attitudes Toward Treatment and Reimbursement in the Cost-Constrained EU5?) | Physician &#038; Payer Forum | EU5 | 2014"},"content":{"rendered":"<p>In January 2014, the European Medicines Agency granted marketing authorization to the first nucleotide polymerase inhibitor, sofosbuvir (Gilead\u2019s Sovaldi), for the treatment of hepatitis C virus (HCV) genotypes 1-6. Sofosbuvir\u2019s approval heralds the all-oral, interferon (IFN)-free era of HCV treatment in Europe, an era that has been boosted by the approval of additional direct-acting antiviral (DAA) combination regimens\u2014Janssen\/Medivir\u2019s Olysio (simeprevir), an improved protease inhibitor, and Bristol-Myers Squibb\u2019s Daklinza (daclatasvir), the first NS5A inhibitor. Although all-oral, IFN-free regimens will dramatically improve treatment outcomes for HCV patients, they are expected to carry substantial price premiums over the current standards of care. With additional IFN-free agents set to reach the market in the near term\u2014Gilead\u2019s Harvoni, a fixed-dose combination of sofosbuvir and the NS5A inhibitor ledipasvir, and AbbVie\u2019s IFN-free combination of paritaprevir (ritonavir-boosted ABT-450), ombitasvir (ABT-267), and dasabuvir (ABT-333)\u2014the HCV field is once again poised to undergo a radical shift in treatment practice. This report examines levers to optimize market access in the EU5 (France, Germany, Italy, Spain, and the United Kingdom).<\/p>\n","protected":false},"template":"","class_list":["post-391501","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-hepatitis-c-virus","biopharma-geography-us","biopharma-date-574"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391501","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391501\/revisions"}],"predecessor-version":[{"id":576989,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391501\/revisions\/576989"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=391501"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}